HomeInsightsStock Comparison

Astrazeneca Pharma India Ltd vs Pfizer Ltd Stock Comparison

Astrazeneca Pharma India Ltd vs Pfizer Ltd Stock Comparison

Last Updated on: Jul 19, 2025

Key Highlights

  • The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 9110 as of 18 Jul 15:30.
  • The P/E Ratio of Astrazeneca Pharma India Ltd changed from 82.8 on March 2020 to 0 on March 2025 . This represents a CAGR of -100.00% over 6 yearsThe P/E Ratio of Pfizer Ltd changed from 36.2 on March 2020 to 23.9 on March 2025 . This represents a CAGR of -6.69% over 6 years.
  • The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 5978 crore on March 2020 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 6 yearsThe Market Cap of Pfizer Ltd changed from ₹ 18411 crore on March 2020 to ₹ 18317 crore on March 2025 . This represents a CAGR of -0.09% over 6 years.
  • The revenue of Astrazeneca Pharma India Ltd for the Mar '25 is ₹ 496.63 crore as compare to the Dec '24 revenue of ₹ 448.27 crore. This represent the growth of 10.79% The revenue of Pfizer Ltd for the Mar '25 is ₹ 809.3 crore as compare to the Dec '24 revenue of ₹ 580.75 crore. This represent the growth of 39.35%.
  • The ebitda of Astrazeneca Pharma India Ltd for the Mar '25 is ₹ 96.84 crore as compare to the Dec '24 ebitda of ₹ 51.42 crore. This represent the growth of 88.33% The ebitda of Pfizer Ltd for the Mar '25 is ₹ 444.89 crore as compare to the Dec '24 ebitda of ₹ 188.75 crore. This represent the growth of 135.7%.
  • The net profit of Astrazeneca Pharma India Ltd changed from ₹ 53.86 crore to ₹ 58.25 crore over 8 quarters. This represents a CAGR of 4.00% The net profit of Pfizer Ltd changed from ₹ 93.53 crore to ₹ 330.94 crore over 8 quarters. This represents a CAGR of 88.10% .
  • The Dividend Payout of Astrazeneca Pharma India Ltd changed from 3.46 % on March 2020 to 0 % on March 2025 . This represents a CAGR of -100.00% over 6 yearsThe Dividend Payout of Pfizer Ltd changed from 296.54 % on March 2020 to 98.34 % on March 2025 . This represents a CAGR of -16.80% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Astrazeneca Pharma India Ltd

  • AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
  • The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
  • The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
  • Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Pfizer Ltd

  • Pfizer Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical products.
  • The Company offer a portfolio of 150 specialised medicines in 15 therapeutic areas across 4 business categories.
  • It has its own manufacturing facility at Goa and Thane.
  • It has the distinction of being the first pharmaceutical company in India to start clinical research.
  • The Company sells products in nearly 185 countries having 43 manufacturing sites globally.

Astrazeneca Pharma India Ltd News Hub

News

AstraZeneca Pharma gets CDSCO approval to import Durvalumab Solution

Through this approval, Durvalumab in combination with carboplatin and paclitaxel is indica...

Read more

02 Jul 2025 10:26

News

Astrazeneca Pharma India Ltd leads losers in 'A' group

Orient Cement Ltd, India Cements Ltd, Concord Biotech Ltd and ERIS Lifesciences Ltd are am...

Read more

20 Jun 2025 15:00

News

AstraZeneca Pharma slides as MD Sanjeev Panchal steps down; Praveen Rao Akkinepally to take charge

Panchal is set to transition to a global role within the AstraZeneca Group, based in Gaith...

Read more

10 Jun 2025 09:49

News

Astrazeneca Pharma India Ltd Spurts 7.28%

Astrazeneca Pharma India Ltd gained 7.28% today to trade at Rs 8545.4. The BSE Healthcare ...

Read more

02 Jun 2025 09:30

News

AstraZeneca Pharma soars after Q4 PAT jumps 48% YoY

Profit before tax (PBT) stood at Rs 78.47 crore in Q4 FY25, up 44.35% year-on-year, and up...

Read more

02 Jun 2025 10:10

News

Volumes soar at Astrazeneca Pharma India Ltd counter

Max Healthcare Institute Ltd, Godrej Consumer Products Ltd, Mphasis Ltd, Indraprastha Gas ...

Read more

02 Jun 2025 11:00

Pfizer Ltd News Hub

News

Pfizer to hold AGM

Pfizer announced that the 74th Annual General Meeting(AGM) of the company will be held on ...

Read more

21 May 2025 11:43

News

Board of Pfizer recommends special dividend

Pfizer announced that the Board of Directors of the Company at its meeting held on 19 May ...

Read more

20 May 2025 12:46

News

Board of Pfizer recommends special dividend

75th year of Pfizer announced that the Board of Directors of the Company at its meeting he...

Read more

20 May 2025 12:46

News

Board of Pfizer recommends final dividend

Pfizer announced that the Board of Directors of the Company at its meeting held on 19 May ...

Read more

20 May 2025 12:47

News

Pfizer gallops after good Q4 outcome

Pfizer reported an exceptional profit of Rs 172.81 crore in Q4 March 2025, primarily due t...

Read more

20 May 2025 12:57

News

Volumes jump at Pfizer Ltd counter

BASF India Ltd, NLC India Ltd, Zensar Technologies Ltd, Newgen Software Technologies Ltd a...

Read more

20 May 2025 14:30

SWOT Analysis Of Pfizer Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Pfizer Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Astrazeneca Pharma India Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Astrazeneca Pharma India Ltd and Pfizer Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Pfizer Ltd?

Market cap of Astrazeneca Pharma India Ltd is 22,777 Cr while Market cap of Pfizer Ltd is 24,319 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Pfizer Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Pfizer Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Pfizer Ltd?

As of July 19, 2025, the Astrazeneca Pharma India Ltd stock price is INR ₹9110.8. On the other hand, Pfizer Ltd stock price is INR ₹5315.9.

How do dividend payouts of Astrazeneca Pharma India Ltd and Pfizer Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Pfizer Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions